Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Division of Infectious Diseases
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey
Director, Scientific Services
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.
This program has been made available online.
Slides from Dr Milena Murray and Clinical Care Options (CCO): Data suggests patient factors that may inform candidacy for LA CAB + RPV as a treatment option
Dr David E. Griffith describes the complex role of in vitro susceptibility testing in the management of NTM lung disease, from Clinical Care Options (CCO)
Expert recap of new data on rapid ART with BIC/FTC/TAF from EACS 2021, from Dr Monica Gandhi at Ward 86 and Clinical Care Options (CCO)
Commentary from Dr Juan Luis Mosqueda Gomez on the latest findings from the IMEA 055 FAST study presented at EACS 2021 and how test-and-treat strategies could improve patient care and virologic suppression in Mexico, from Clinical Care Options (CCO)